
-
India-Pakistan tensions hit tourism in Kashmiri valley
-
Bangladesh Islamists rally in show of force
-
Zelensky says won't play Putin's 'games' with short truce
-
Cardinals meet ahead of papal election
-
Pakistan tests missile weapons system amid India standoff
-
France charges 21 prison attack suspects
-
Pakistan military says conducts training launch of missile
-
Lives on hold in India's border villages with Pakistan
-
Musk's dreams for Starbase city in Texas hang on vote
-
Rockets down Warriors to stay alive in NBA playoffs
-
Garcia beaten by Romero in return from doping ban
-
Inflation, hotel prices curtail Japanese 'Golden Week' travels
-
Trump's next 100 days: Now comes the hard part
-
Mexican mega-port confronts Trump's tariff storm
-
Trump's tariffs bite at quiet US ports
-
Ryu stretches lead at LPGA Black Desert Championship
-
Singapore votes with new PM seeking strong mandate amid tariff turmoil
-
Five things to know about the Australian election
-
Scheffler fires 63 despite long delay to lead CJ Cup Byron Nelson
-
GISEC Global 2025: Dubai Mobilises Global Cyber Defence Leaders to Combat AI-Driven Cybercrime and Ransomware
-
Israel launches new Syria strikes amid Druze tensions
-
Finke grabs 400m medley victory over world record-holder Marchand
-
Apple eases App Store rules under court pressure
-
Polls open in Australian vote swayed by inflation, Trump
-
Russell clocks second fastest 100m hurdles in history at Miami meeting
-
Germany move against far-right AfD sets off US quarrel
-
Billionaire-owned Paris FC win promotion and prepare to take on PSG
-
Teenager Antonelli grabs pole for Miami sprint race
-
Man City climb to third as De Bruyne sinks Wolves
-
Mercedes' Wolff backs Hamilton to come good with Ferrari
-
'Devastated' Prince Harry says no UK return but seeks reconciliation
-
Elway agent death likely accidental: report
-
Turkish Cypriots protest new rule allowing hijab in school
-
Germany's AfD dealt blow with right-wing extremist label
-
Trump NASA budget prioritizes Moon, Mars missions over research
-
Hard-right romps through UK polls slapping aside main parties
-
Rangers hire two-time NHL champion Sullivan as coach
-
Haaland on bench for Man City as striker returns ahead of schedule
-
US designates two Haitian gangs as terror groups
-
Lower profits at US oil giants amid fall in crude prices
-
NBA icon Popovich stepping down as Spurs coach after 29 seasons
-
'Devastated' Prince Harry says no return to UK but seeks royal reconciliation
-
Grande scratched from Kentucky Derby
-
Carney vows to transform Canada economy to withstand Trump
-
Prince Harry says he would 'love' to reconcile with family
-
Major offshore quake causes tsunami scare in Chile, Argentina
-
GM cuts shift at Canada plant over 'evolving trade environment'
-
F1 extends deal to keep Miami GP until 2041
-
Popovich mixed toughness and spirit to make NBA history
-
US asks judge to break up Google's ad tech business

Japan biochemist who discovered statins, Akira Endo, dies
Japanese biochemist Akira Endo, who discovered cholesterol-lowering statins, has died aged 90, his former student and colleague said on Tuesday.
Statins, which can prevent heart attacks or strokes, are among the most commonly prescribed drugs worldwide.
Keiji Hasumi, a professor who was a long-time associate of Endo, said the scientist had died on June 5.
"His work was truly great. Statins didn't exist before Endo," Hasumi told AFP. "It has the same value and impact as the discovery of penicillin."
Johns Hopkins Medicine says more than 200 million people take statins. Studies say the global market for them was worth $15 billion in 2023 and is expected to grow.
Endo experimented on thousands of microbes to reach his 1973 discovery of mevastatin -- an agent derived from penicillin that reduces so-called "bad" cholesterol in the blood.
The researcher "was a tough, strict person. He was insightful and perceptive," and "able to see the hidden essence of things", Hasumi said.
Endo was born in 1933 to a farming family in rural northern Japan.
His ambitions began early thanks to his grandfather, who was interested in medicine and became a "great home teacher", Endo said in a 2008 autobiographical essay.
As a student, Endo became interested in antibiotics like penicillin, "deeply impressed" by how many lives they had saved, his essay in the journal Nature Medicine said.
Endo carried out research in New York in the late 1960s, when coronary heart disease was the main cause of US deaths.
"I often saw ambulances coming to take elderly people who had suffered a heart attack to hospital", which "made me realise the importance of developing a cholesterol-lowering drug", he said.
Endo worked at the Tokyo University of Agriculture and Technology, which issued a statement expressing condolences over his death, and at Japanese drugmaker Sankyo, now a part of Daiichi-Sankyo.
He spent two years testing 6,000 strains of microbe in the search for a new drug that could help achieve his goal before finally finding mevastatin.
Conflicting reports on the benefits and potential harms of statins in recent years have prompted some people prescribed the drugs to stop taking them.
"Are statins safe? For most people, the answer is a resounding yes, according to a 2014 Johns Hopkins meta-analysis of 20 years worth of published research," the US university says.
Endo was a strong candidate for a Nobel Prize, but never won. In a report on his death, Japanese broadcaster NHK noted Endo had received other accolades, including being honoured as a Person of Cultural Merit by the government in 2011.
His discovery "was the result of many twists and turns", Hasumi said.
"He reached his goal by overcoming so many challenges, without which medicines cannot be created, I think I remember him saying."
Y.Kobayashi--AMWN